Article
Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas.
Nature communications - 10 May 2021
Udugama M, Hii L, Garvie A, Cervini M, Vinod B, Chan F-L, Das P P, Mann J R, Collas P, Voon H P J, Wong L H
Abstract excerpt
Alternative Lengthening of Telomeres (ALT) is a telomere maintenance pathway utilised in 15% of cancers. ALT cancers are strongly associated with inactivating mutations in ATRX; yet loss of ATRX alone is insufficient to trigger ALT, suggesting that additional cooperating factors are involved. We identify H3.3G34R and IDH1/2 mutations as two such factors in ATRX-mutated glioblastomas. Both mutations are capable of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.